IndraLab

Statements

ATXN3 activates ZFYVE9. 1 / 1

| 1

reach

"Additionally, in an open-label clinical trial, it was demonstrated that subcutaneous IGF-1 treatment in SCA3/MJD patients could increase the SARA score after only 8 months; however, this benefit faded after 10–20 months [68]."

| PMC

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

ATXN3 activates ZFYVE9. 1 / 1

INDRA sources:

Databases

Reading